Paper · 34529489
The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation.
Martin TD and 8 others. Science, 2021. Cited by 128 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation. Papers, record 34529489. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34529489
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation.
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinogenesis | Major topic |
| Gene Silencing | Major topic |
| Genes, Tumor Suppressor | Major topic |
| Immune Evasion | Major topic |
| Neoplasms, Experimental | Major topic |
| Animals | |
| CRISPR-Cas Systems | |
| Cell Line, Tumor | |
| Chemokine CCL2 | |
| Female | |
| GTP-Binding Protein alpha Subunits, G12-G13 | |
| Humans | |
| Mammary Neoplasms, Experimental | |
| Mice | |
| Mice, Inbred BALB C | |
| Mice, Inbred C57BL | |
| Mice, SCID | |
| Neoplasm Transplantation | |
| Selection, Genetic | |
| Tumor Microenvironment |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| 27144 | Cancer Research UK | United Kingdom | PubMed | PubMed | |
| U01 CA199252 | NCI NIH HHS | United States | U01CA199252 | PubMed and NIH | NIH RePORTER |
| Howard Hughes Medical Institute | United States | PubMed | PubMed |
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections3
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 34,529,483 | Opposing roles of the immune system in tumors. | https://conductscience.org/library/papers/34529483 | PubMed |
| Comment in | 34,611,351 | Under pressure. | https://conductscience.org/library/papers/34611351 | PubMed |
| Comment in | 35,027,544 | A new perspective on immune evasion: escaping immune surveillance by inactivating tumor suppressors. | https://conductscience.org/library/papers/35027544 | PubMed |
References72
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22,628,553 | Recurrent hemizygous deletions in cancers may optimize proliferative potential. | Science | 2012 | https://conductscience.org/library/papers/22628553 | PubMed |
| 2 | 30,837,996 | Genome-Wide CRISPR Screening Identifies JAK1 Deficiency as a Mechanism of T-Cell Resistance. | Front Immunol | 2019 | https://conductscience.org/library/papers/30837996 | PubMed |
| 3 | 31,160,587 | Tumour-associated macrophages exhibit anti-tumoural properties in Sonic Hedgehog medulloblastoma. | Nat Commun | 2019 | https://conductscience.org/library/papers/31160587 | PubMed |
| 4 | 29,719,257 | CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype. | Cell Rep | 2018 | https://conductscience.org/library/papers/29719257 | PubMed |
| 5 | 20,844,553 | Harnessing transposons for cancer gene discovery. | Nat Rev Cancer | 2010 | https://conductscience.org/library/papers/20844553 | PubMed |
| 6 | 10,591,652 | Mouse models of tumor development in neurofibromatosis type 1. | Science | 1999 | https://conductscience.org/library/papers/10591652 | PubMed |
| 7 | 31,068,700 | Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | https://conductscience.org/library/papers/31068700 | PubMed |
| 8 | 28,196,594 | Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. | Cancer Cell | 2017 | https://conductscience.org/library/papers/28196594 | PubMed |
| 9 | 29,301,958 | A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. | Science | 2018 | https://conductscience.org/library/papers/29301958 | PubMed |
| 10 | 31,253,869 | Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front. | Oncogene | 2019 | https://conductscience.org/library/papers/31253869 | PubMed |
1 to 10 of 72
See all 72 referencesCited by105
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 128 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,903,966 | Interactions between microbiota and innate immunity in tumor microenvironment: Novel insights into cancer progression and immunotherapy. | Hlife | 2025 | https://conductscience.org/library/papers/42903966 | PubMed |
| 42,829,916 | CD112 Lactylation Drives Dual Immune Evasion From CD8+ T Cells and NK Cells. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/42829916 | PubMed |
| 42,703,176 | An Insight into the Emerging Role of Extracellular Vesicle-derived Noncoding RNAs in Colorectal Cancer. | Microrna | 2026 | https://conductscience.org/library/papers/42703176 | PubMed |
| 42,685,085 | Changes in the transcriptome and synthetic lethal dependencies following KRAS mutant expression reveal profound tissue specificity. | Proc Natl Acad Sci U S A | 2026 | https://conductscience.org/library/papers/42685085 | PubMed |
| 42,539,061 | EMT activates ER-to-Golgi trafficking through upregulation of REEP2 to promote lung cancer progression. | Res Sq | 2026 | https://conductscience.org/library/papers/42539061 | PubMed |
| 42,420,609 | Breast cancer driver genes found by screening chromosome aberrations in vivo. | Nature | 2026 | https://conductscience.org/library/papers/42420609 | PubMed |
| 42,297,823 | Tumor suppressor genotype influences the extent and mode of immunosurveillance in lung cancer. | Nat Commun | 2026 | https://conductscience.org/library/papers/42297823 | PubMed |
| 42,270,598 | CFTR-driven immune microenvironment reprogramming synergizes with anti-PD-L1 antibody in hepatocellular carcinoma. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/42270598 | PubMed |
| 42,225,068 | Temporal control of sgRNA library activation unlocks large-scale in vivo CRISPR screens. | Cell Rep Methods | 2026 | https://conductscience.org/library/papers/42225068 | PubMed |
| 42,204,538 | The mycobiome, virome and archaeome in gastrointestinal cancers: molecular pathogenesis and therapeutic intervention. | Mol Cancer | 2026 | https://conductscience.org/library/papers/42204538 | PubMed |
1 to 10 of 105
See all 105 cited byGenes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34529489
GET https://conductscience.org/api/papers/v1/34529489/references?page=2